Our Blog

Welcome to the CERES Regulatory Services blog! Here, you’ll find a wide range of articles and resources on Accelerated Approval Pathways and FDA Fast Track Designation, FDA Breakthrough Therapy Designation, FDA Priority Review Designation, FDA Approval Process, Regulatory Strategy for Therapeutics (Drugs, Biologics, Vaccines, Medical Devices, Cell and Gene Therapy and Advanced Tissue Products), Nonclinical Development, Clinical Development, FDA Meetings, Drug Development Pathways, Expedited Drug Approval, Innovative Therapies Development, NDA and BLA Submission Strategies, FDA Regulatory Guidance, FDA Accelerated and Expedited programs and Strategies of Interest to the Regulatory Scientist.

The Blenrep Resubmission Journey: From FDA CRL to Approval 

Categories: Clinical Studies
46

Hello Regulatory Scientists, 

Today, let’s explore the journey of Blenrep (belantamab mafodotin) from receiving an FDA Complete Response Letter (CRL) to achieving approval. This case study provides valuable insights and lessons that can guide companies developing new drugs today. 

Regulatory History and Initial Submission 

Drug: Blenrep (belantamab mafodotin) 
Mechanism of Action: Antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA), delivering the cytotoxic agent mafodotin to kill cancer cells 
Indication: Treatment of relapsed or refractory multiple myeloma 
Initial Submission Date: September 2019 

The Complete Response Letter (CRL) 

CRL Date: March 2020 
CRL Concerns: 

  1. Manufacturing Process: The FDA raised concerns about the quality and consistency of the drug’s manufacturing process. 
  1. Safety Data: Request for more comprehensive safety data, particularly regarding ocular toxicity observed in clinical trials. 
  1. Risk Management Plan: Need for a detailed risk management plan to monitor and mitigate potential adverse effects, especially related to eye health. 

Resubmission Strategy 

GlaxoSmithKline (GSK), the company behind Blenrep, implemented a comprehensive strategy to address the FDA’s concerns: 

  1. Manufacturing Process Improvements: Made significant enhancements to the manufacturing process to ensure consistency and quality. 
  1. Enhanced Safety Monitoring: Provided additional data and analyses on the safety profile, focusing on managing and mitigating ocular toxicity. 
  1. Risk Management Plan: Developed a robust risk management plan, including monitoring guidelines, patient education materials, and specific measures for ocular health. 
  1. Continuous FDA Engagement: Maintained open lines of communication with the FDA to ensure alignment on the resubmission strategy and clarify any outstanding questions. 

Resubmission Date: June 2020 

Outcome 

Approval Date: August 2020 
Blenrep was approved for the treatment of relapsed or refractory multiple myeloma, providing a new and effective option for patients who have exhausted other treatments. 

Lessons Learned 

The journey of Blenrep from CRL to approval highlights several key lessons for drug developers: 

  1. Manufacturing Process Improvements: Ensuring the quality and consistency of the manufacturing process is crucial. Proactive improvements and rigorous quality control measures can prevent setbacks. 
  1. Enhanced Safety Monitoring: Providing extensive safety data and developing strategies to manage specific adverse effects, such as ocular toxicity, is essential. 
  1. Effective Risk Management: Developing and implementing a detailed risk management plan can help mitigate potential adverse effects and ensure patient safety. 
  1. Continuous FDA Engagement: Maintaining open and ongoing communication with the FDA helps align development efforts with regulatory expectations. 
  1. Proactive Quality Control: Implementing stringent quality control measures ensures the consistency and reliability of the drug’s production. 

Relevance for Current Drug Developers 

For companies developing drugs today, the Blenrep case underscores the importance of strategic planning and meticulous attention to detail in the regulatory process. Here are some takeaways to help avoid a CRL and achieve first-cycle approval: 

  1. Thorough Pre-Submission Preparation: Ensure that all aspects of your submission, including manufacturing processes and safety data, meet FDA standards. 
  1. Proactive Risk Management: Identify and address potential risks early in the development process to prevent issues from arising during FDA review. 
  1. Engage with the FDA Early and Often: Regular interactions with the FDA can provide valuable guidance and help steer the development process. 
  1. Invest in Quality Data: Prioritize the collection of high-quality, detailed safety and efficacy data to support the submission. 
  1. Utilize Advisory Committees: Seek feedback from advisory committees to validate data and address potential concerns, even if formal hearings are not required. 

By learning from the Blenrep resubmission experience, current drug developers can better navigate the regulatory landscape, avoid common pitfalls, and increase the likelihood of a successful first review cycle approval. 

Stay diligent and strategic, 

CERES Regulatory Services 

Picture of Asad Khan
Asad Khan